BIT's 2nd International Biotechnology Congress-2018 (IBC-2018)

BIT's 2nd International Biotechnology Congress-2018 (IBC-2018), with the theme of “From Innovation to Applications” will be held during October 14-16, 2018 at Fukuoka, Japan.

This unique international conference creates a great platform to researches, scientists, academicians and industry experts to share experiences, discuss research findings and acquire the desired knowledge for practical exercise. IBC-2018 is a dedicated event where you will have the opportunity to learn about new developments in the field of Biotechnology, Gene and Life Sciences, and share aspects of your own work by submitting a poster or oral presentation. With the participation of outstanding international experts, we hope productive discussions would stimulate new creative ideas to translate new discoveries into better practice and application. We hope your participation would contribute to your professional development and relationships.

Wish you enjoy the conference!

Keynote Speakers of IBC-2018
Dr. Tim Hunt
Emeritus Group Leader
Clare Hall Laboratories

Nobel Prize laureate in Physiology or Medicine, 2001
Dr. Behzad Mahdavi
VP Strategic Innovation & Alliances
Lonza Walkersville, Inc.
Dr. Reiko Kuroda
Tokyo University of Science
Dr. Kazuhide Inoue
Executive Vice President
Kyushu University
Dr. C.-K. James Shen
Distinguished Research Fellow
Academia Sinica
Dr. William G. Rice
Chairman, President and CEO
Aptose Biosciences Inc.

Sir Richard Timothy Hunt, FRS FMedSci FRSE (born 19 February 1943) is a British biochemist and molecular physiologist. He was awarded the 2001 Nobel Prize in Physiology or Medicine with Paul Nurse and Leland H. Hartwell for their discoveries of protein molecules that control the division of cells. In particular, Hunt discovered what he called cyclin: a protein in fertilised sea urchin eggs which cyclically aggregates and is depleted during cell division cycles. Following his PhD, Hunt returned to New York to work with London, in collaboration with Nechama Kosower, her husband Edward Kosower, and Ellie Ehrenfeld. While there, they discovered that tiny amounts of glutathione inhibited protein synthesis in reticulocytes and that tiny amounts of RNA killed the synthesis altogether. After returning to Cambridge, he again began work with Tony Hunter and Richard Jackson, who had discovered the RNA strand used to start haemoglobin synthesis. After 3–4 years, the team discovered at least two other chemicals acting as inhibitors.Hunt was elected a member of the European Molecular Biology Organization (EMBO) in 1978, serving as a member of the organisation's Fellowship Committee 1990–1993, its Meeting Committee 2008–2009, and its governing body, the Council, 2004–2009. He was elected a Fellow of the Royal Society (FRS) in 1991.

Behzad Mahdavi is serving as Vice President of Strategic Innovation & Alliances at Lonza, one of the world's leading suppliers to the Pharma&Biotech and Specialty Ingredient markets, as a Chairman of the Board of Exosomics, an innovator leader in the field of Liquid Biospy and as a member of Investment and Advisory committee for C3E Venture Capital Fund, one of the most active private fund in Canada. He began in his current position at Lonza in 2010 after three years serving as Head of Lonza Canada. Prior to joining Lonza, he was CEO of SAM Electron Technologies, a venture capital-backed company in the Life Sciences field, which was acquired in 2007 by a multinational company. During his entire career, Behzad worked for several private organizations, governmental companies and venture capital firms in different capacities as senior executive, advisor, CEO and board member.  In these roles, he was involved in leading, managing and advising technological start-ups/companies in fund raising, strategic business development, efficient innovation management and commercialization/spinoff to create new profitable growth axis. He earned his MBA from the University of Quebec in Montreal, Canada, his Ph.D. in Chemistry from University of Sherbrooke, Canada, his M.S. in Industrial Chemicals & Environment from the University of Rennes, France and his B.Sc. in Chemical Engineering from ENSCR, France.

Dr. Reiko Kuroda, Professor at Research Institute for Science and Technology at Tokyo University of Science/ Professor Emeritus at The University of Tokyo, has obtained Ph.D. in Chemistry from The University of Tokyo. She worked at King’s College London in the Department of Chemistry and then Biophysics, as well as at Institute of Cancer Research, UK. Returned to Japan as an Associate Professor, and became a full professor in 1992, the first female full professor in the field of natural sciences at the University of Tokyo. She is a chemist as well as biologist and her main research interest is chiromorphology. In addition to her scientific activity, she is involved in science policy, higher education policy, science communication and promotion of STEM career especially for women/girls. L’Oreal UNESCO Women in Science Award (2013), Vice president of ICSU (International Council for Science, 2008-11), Scientific Advisory Board to the UN Secretary General (2013-16) etc.In Japan, member of Council of Science and Technology Policy (2001-7), and Ambassador of WINDS (Women’s Initiative in Developing STEM Career) (2016- ). She is a member of the Royal Swedish Academy of Sciences.

Professor Kazuhide Inoue is the Executive Vice-President of Kyushu University. ProfessorInoue has published over 200 papers on the subject of the function of purinergic receptors in CNS, especially in pain signaling. Inoue’s group has found that P2X4 receptors in spinal microglia has important role in the expression of neuropathic pain that is often refractory to treatment with NSAIDs and opioids, and the stimulation of P2Y6 receptors causes microglial phagocytosis.In 1975, he graduated School of Pharmaceutical Sciences, Kyushu University, and 1978 he started to research at National Institute of Health Sciences, Japan. After obtaining Ph.D from Kyusyu University in 1985, he studied abroad in NIH, USA, as a visiting fellow until 1987. He again studied abroad in University College London (Prof. G Burnstock), as an honorary research fellow from 1991 till 1992. In 2000, he became a professor of Graduate School of Pharmaceutical Sciences, Kyushu University. From 2014 till now, he works asthe Executive Vice-President of Kyushu University. He was awarded Science Technology Award from the Minister of Education, Culture, Sports, Science and Technology-Japan in 2007, the 3rd SetsuroEbashi Prize of The Japanese Pharmacological Society in 2010, Medal from His Majesty the Spanish Emperor as an honor of Royal Academy of Pharmacy in 2010, The Pharmaceutical Society of Japan Award in 2013, and Medal with Purple Ribbon from His Majesty the Emperor in 2014.

James Shen is a molecular geneticist working on gene regulation. He has a BS degree from the Dept. of Chemistry, National Taiwan University and a PhD degree from the Chemistry Dept. of the University of California, Berkeley. He received his postdoctoral training at Cal Tech and was a faculty at the University of California, Davis from 1981-1999. From 1995-2004, he was the Director of the Institute of Molecular Biology (IMB), Academia Sinica, Taipei, Taiwan. He is now a Distinguished Research Fellow at IMB. His research interests cover the molecular and cellular basis of hematopoietic gene regulation, neuronal plasticity, development, and cell differentiation in relation to chromatin structure and epigenetics. He is an Academician of the Academia Sinica, an elected Fellow of the American Association for the Advancement of Science (AAAS), and an elected Fellow of the Third World Academy of Sciences.

Dr. William G. Rice serves as Chairman, President and CEO of Aptose Biosciences Inc., a publicly traded clinical stage biotechnology company developing first-in-class targeted agents to treat life-threatening hematological malignancies. Prior to Aptose, Dr. Rice served as Chairman, President, CEO of Cylene Pharmaceuticals, Inc. and led the development and sale of small molecule therapeuticsthat exploit kinase pathways and non-genotoxic mechanisms for activating p53 to kill cancer cells. Before Cylene, Dr. Rice was Founder, President, CEO and Director of Achillion Pharmaceuticals, Inc. Prior to that, he served as Senior Scientist and Head of the Drug Mechanism Laboratory at the National Cancer Institute-Frederick Cancer Research and Development Centerand a Visiting Scientist to the IMCB of Singapore, and as a professorof Pediatric Hematology and Oncology at Emory University School of Medicine. Dr.Rice has held leadership roles in industry, government and academic sectors and accrued more than 30 years of executive, operational, business development, financial, product research, and product development skills.Over the course of his career, Dr. Rice identified multiple new molecular drug targets, delivered multiple first-in-class drugs to the clinic, and published peer-reviewed findings in Science, Nature, Cell, Nature Medicine, Proceedings of the National Academy of Sciences, among other prestigious journals. Dr. Rice holds a Ph.D. in Biochemistry from Emory University and was a postdoctoral trainee in the Department of Internal Medicine at the University of Michigan Medical Center.

Renowned Speakers of IBC-2018 Dr. Robin Vercruse
Fuel Freedom Foundation
Dr. Youngeun Kwon
Dongguk University
South Korea
Dr. Grigory Arzumanyan
Joint Institute for Nuclear Research (JINR)
Dr. Chin-Tarng Lin
National Taiwan University Hospital
Dr. Babkin V.A.
Russian Academy of Sciences
Dr. Yi Sun
Zhejiang University
Dr. Karine De Oliveira Vigier
Université de Poitiers-CNRS- IC2MP
Dr. Behzad Mahdavi
Lonza Walkersville, Inc.
USA Dr. Tey Lai Hock
UniversitiTunku Abdul Rahman, Malaysia
Dr. Kunio Yoshikawa
Tokyo Institute of Technology
Dr. Trond O. Jorgensen
Murdoch University
Dr. Hirotsugu Fujitani
Waseda University
Picture Dr. Jason McDevitt
William & Mary
Dr. Dan Pettersson
Novozymes A/S
Joe Zhou Dr. Joe Zhou
Genor Biopharma
Dr. Rolf G. Werner
University of Tuebingen
Dr. Andrew Ellis
Biocatalysts Ltd
Ylwa Alwarsdotter Dr. Ylwa Alwarsdotter
Dr. Rolf G. Werner
Senior Vice President
BoehringerIngelheim GmbH
Mr. Richard Fish
Alter NRG, Canada
Dr. Ping Xu
Professor & Director
National Center for Protein Sciences Beijing, China
Previous Event Report
Exhibition and Sponsorship

As part of the IBC-2018, an exhibition space will provide a unique opportunity for exhibitors to showcase their products and services to participants with interests in all areas of biotechnology. Developed to offer comfort to delegates while maximizing exhibitor exposure, the coffee breaks and poster sessions will all take place in the exhibition area promoting frequent and repeated opportunities for delegates to visit the exhibits.

Exhibitors' Advantages
• The exhibition will be visited by participants of the conference it means by your authentic target group from China and other countries.
• The exhibitors have the opportunity to present their exhibits more detailed, and have the opportunity for longer discussion with inquiring visitors - in most cases specialists - than during session discussions. More>>

IBC-2018 is one of the most effective international marketing platforms in the field of biotechnology and life science, which offers a wide range of sponsoring categories for branding and highlighting your company in order to achieve the best publicity. More>>

Introduction to Fukuoka

Fukuoka is the capital city of Fukuoka Prefecture, situated on the northern shore of the Japanese island of Kyushu. It is the most populous city on the island, followed by Kitakyushu. It is the largest city and metropolitan area west of Keihanshin. The city was designated on April 1, 1972, by government ordinance. Greater Fukuoka, with 2.5 million people (2005 census), is part of the heavily industrialized Fukuoka–Kitakyushu zone as well as Northern Kyushu.As of 2015, Fukuoka is Japan’s fifth largest city, having passed the population of Kobe. As of July 2011, Fukuoka passed the population of Kyoto. Since the founding of Kyoto in 794, this marks the first time that a city west of the Kinki region has a larger population than Kyoto. In ancient times, however, the area near Fukuoka, the Chikushi region, was thought by some historians to have possibly been even more influential than the Yamato region.

News Released

Tentative Scientific Program Released
Keynote Speakers Released
Academicians Forum Speakers Released
Hotel Released
Speaking proposals are now being accepted, download the Format of Abstract and CV
Call for Exhibitors and Sponsors
Call for Collaborative Partners, Media and Journals

Hosting Organization
Official Travel Agency
BIT’s Upcoming Events
Contact Us

Add: East Area, F11, Building 1, Dalian Ascendas IT Park, 1 Hui Xian Yuan, Dalian Hi-tech Industrial Zone, LN 116025, China]
Tel: 0086-411-84799609, Fax: 0086-411-84796897
Copyright © 2017-2018 BIT Congress Inc.